Meropenem Aptapharma

Meropenem, the active ingredient in Meropenem Aptapharma, is a carbapenem antibiotic presented as an intravenous solution for intravenous use. It is employed to treat severe bacterial infections, including intra‑abdominal, urinary tract, respiratory, central nervous system infections, and sepsis, in hospitalized adult patients.

GNH USA supplies Meropenem Aptapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, ensuring quality, traceability and regulatory compliance across global markets. Our distribution network adheres to stringent cold‑chain standards where required and provides reliable logistics support for timely delivery.

Meropenem is a carbapenem antibiotic used to treat serious bacterial infections. - Complicated intra‑abdominal infections: eradicates Gram‑negative and anaerobic pathogens, helping resolve infection and prevent progression. - Complicated urinary tract infections: eliminates resistant uropathogens, facilitating rapid clinical improvement. - Nosocomial pneumonia: provides broad‑spectrum coverage against hospital‑acquired respiratory pathogens. - Meningitis: penetrates the cerebrospinal fluid to achieve bactericidal activity against causative organisms. - Severe sepsis and septic shock: offers rapid bacterial kill to support hemodynamic stabilization.

Adverse reactions may occur with meropenem therapy.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: may be watery and self‑limiting. - Headache: transient and usually resolves. - Rash: erythematous skin eruption. - Elevated liver enzymes: transient transaminase rise. - Injection site phlebitis: local irritation at IV site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction requiring immediate intervention. - Clostridioides difficile‑associated diarrhea: potentially life‑threatening colitis. - Seizures: especially in patients with CNS disorders or high doses. - Acute renal impairment: may worsen existing kidney dysfunction. - Hepatic failure: rare but serious liver injury. - Neutropenia: marked reduction in neutrophil count.

Careful assessment and monitoring are required when using meropenem. - Renal function: adjust dose in patients with impaired renal clearance. - Allergy: avoid in individuals with known hypersensitivity to carbapenems or β‑lactams. - Seizure risk: monitor patients with a history of CNS disorders or receiving high doses. - Pregnancy: use only if the potential benefit justifies the potential risk to the fetus. - Concurrent nephrotoxic drugs: assess for additive kidney toxicity. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Meropenem may interact with other medicines, requiring vigilance.

Major Interactions (Avoid): - Valproic acid: meropenem can lower valproate levels, increasing seizure risk. - Phenobarbital, phenytoin, carbamazepine: enzyme induction may increase meropenem clearance. - Aminoglycosides or other nephrotoxic agents: additive renal toxicity.

Moderate Interactions (Monitor Closely): - Loop diuretics: monitor renal function and electrolytes. - Warfarin: observe INR for possible anticoagulation changes. - Proton pump inhibitors: although administered intravenously, monitor for any unexpected effects on drug disposition.